Home » Stocks » Pulmatrix

Pulmatrix, Inc. (PULM)

Stock Price: $1.31 USD 0.05 (3.97%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $1.30 -0.01 (-0.76%) Aug 10, 7:46 PM

Stock Price Chart

Key Info

Market Cap 33.55M
Revenue (ttm) 9.35M
Net Income (ttm) -13.45M
Shares Out 25.42M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $1.31
Previous Close $1.26
Change ($) 0.05
Change (%) 3.97%
Day's Open 1.25
Day's Range 1.25 - 1.33
Day's Volume 888,270
52-Week Range 0.61 - 2.06

More Stats

Market Cap 33.55M
Enterprise Value 8.34M
Earnings Date (est) Oct 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.42M
Float 25.54M
EPS (basic) -0.62
EPS (diluted) -0.63
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.68M
Short Ratio 0.30
Short % of Float 1.37%
Beta 1.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.59
PB Ratio 4.73
Revenue 9.35M
Operating Income -13.50M
Net Income -13.45M
Free Cash Flow -12.68M
Net Cash 25.21M
Net Cash / Share 0.98
Gross Margin -52.76%
Operating Margin -144.33%
Profit Margin -143.80%
FCF Margin -135.59%
ROA -23.74%
ROE -84.14%
ROIC 134.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$10.00*
Low
10.0
Current: $1.31
High
10.0
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142012
Revenue7.910.150.340.841.200.35-
Revenue Growth5069.93%-54.33%-59.88%-30.47%241.19%--
Gross Profit7.910.150.340.841.200.35-
Operating Income-20.69-20.40-17.48-24.87-23.02-9.08-0.52
Net Income-20.60-20.56-18.06-27.84-26.17-6.45-0.52
Shares Outstanding16.734.131.941.480.810.020.08
Earnings Per Share-1.23-4.98-9.32-18.80-32.30-345.20-6.50
Operating Cash Flow3.23-16.76-14.48-13.24-12.47-9.17-0.43
Capital Expenditures-0.06-0.02-0.07-0.43-0.27-0.29-
Free Cash Flow3.17-16.78-14.55-13.67-12.74-9.45-0.43
Cash & Equivalents23.442.563.554.1818.900.450.10
Total Debt0.68-3.225.806.7239.70-
Net Cash / Debt22.772.560.33-1.6212.18-39.250.10
Assets36.1014.7215.9816.6644.871.550.15
Liabilities25.082.885.847.9012.2744.770.10
Book Value11.0211.8410.148.7632.61-78.790.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pulmatrix, Inc.
Country United States
Employees 22
CEO Teofilo Raad

Stock Information

Ticker Symbol PULM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PULM

Description

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.